Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks the mitochondrial electron transport chain in Plasmodium parasites, halting ATP production. Proguanil is converted to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme, disrupting DNA synthesis. Together they produce a synergistic effect that kills the parasite.

The dosage of Malarone is determined by the prescribing clinician based on the patient’s age, weight, indication (prevention or treatment), and local resistance patterns. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Malarone in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Malarone, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone combines two agents with distinct mechanisms, offering high efficacy and a lower risk of resistance compared with monotherapy options such as chloroquine or mefloquine. Its safety profile is generally favorable, though tolerability and drug‑interaction considerations differ among alternatives.

Malarone tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Malarone is taken orally with food or a milky drink to improve absorption. The tablets are swallowed whole with a full glass of water. For prophylaxis, dosing typically starts 1–2 days before travel and continues for 7 days after leaving the endemic area.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, hemolysis in patients with G6PD deficiency, and rare blood disorders like neutropenia or thrombocytopenia. Prompt medical attention is required if any severe symptoms develop.

Malarone should be avoided in patients with known hypersensitivity to atovaquone, proguanil, or any component of the formulation, and in individuals with severe renal impairment. Caution is advised for those with G6PD deficiency, significant liver disease, or pregnant and breastfeeding women unless clearly indicated by a physician.